cenacitinib   Click here for help

GtoPdb Ligand ID: 13487

Synonyms: compound 5 [US20210139486]
Compound class: Synthetic organic
Comment: Cenacitinib is the INN for an anti-inflammatory Janus kinase inhibitor. The chemical structure was obtained from WHO proposed INN list 131 (August 2024). It is one of the compounds in Ventyx Biosciences' patent US20210139486A1 [1], that claims Tyk2 pseudokinase inhibitors, Tyk2 being the fourth member of the Janus kinase family. Targeting the pseudokinase domain is a strategy for the development of allosteric inhibitors that can be more selective than active site inhibitors. We predict that cenacitinib is the INN for Ventyx's clinical lead Tyk2 inhibitor VTX958.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 111.61
Molecular weight 431.4
XLogP 1.13
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CNC1=CC(=NC2=C(C=NN12)NC(=O)N[C@@H]3C[C@@H]3F)NC4=CC(=CC5=C4OCCO5)F
Isomeric SMILES FC=1C=C(C2=C(OCCO2)C1)NC3=NC=4N(C(=C3)NC)N=CC4NC(=O)N[C@H]5[C@H](C5)F
InChI InChI=1S/C19H19F2N7O3/c1-22-16-7-15(24-12-4-9(20)5-14-17(12)31-3-2-30-14)27-18-13(8-23-28(16)18)26-19(29)25-11-6-10(11)21/h4-5,7-8,10-11,22H,2-3,6H2,1H3,(H,24,27)(H2,25,26,29)/t10-,11+/m0/s1
InChI Key WMXUGUJEUBVMSQ-WDEREUQCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
VTX958 was progressed as an anti-inflammatory candidate for psoriasis, psoriatic arthritis and Crohn's disease. As of August 2024, clinical evaluation is active only in a Crohn's disease study.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05688852 VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease Phase 2 Interventional Ventyx Biosciences, Inc The Harmony-CD study